Treatment practice in the elderly patient with chronic lymphocytic leukemia - Analysis of the combined SEER and Medicare database

Annals of Hematology

Volumn 93, Issue 8, 2014, Pages 1335-1344

  Satram Hoang, Sacha ^a   Reyes, Carolina ^b,c   Hoang, Khang Q ^a   Momin, Faiyaz ^a   Skettino, Sandra ^b  

^a QD Research Inc   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic lymphocytic leukemia; Comorbidity; Elderly; Survival; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COMORBIDITY; CYCLOPHOSPHAMIDE; DATABASES, FACTUAL; DISEASE MANAGEMENT; DOXORUBICIN; ETHNIC GROUPS; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; PREDNISONE; SEER PROGRAM; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES; VIDARABINE; VINCRISTINE;

EID: 84904732234     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2048-6     Document Type: Article

References (38)

1. Howlader N, Noone A, Krapcho M et al (2011) SEER cancer statistics review, 1975-2009 (vintage 2009 populations). National Cancer Institute, Bethesda
2. Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220-241
3. Yancik R (1997) Epidemiology of cancer in the elderly. Current status and projections for the future. Rays 22(1 Suppl):3-9
4. Thurmes P, Call T, Slager S et al (2008) Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 49(1):49-56 (Pubitemid 351146882)
5. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164-1174
6. Gribben JG (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther 10(9):1389-1394
7. Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(4):498-503
8. Smolej L (2012) Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Pharm Des 18(23):3399-3405
9. Leporrier M (2004) Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 5(Suppl 1):S10-S19
10. Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-IV-18
11. Potosky AL, Riley GF, Lubitz JD et al (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31(8):732-748
12. Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1):198-206 (Pubitemid 11064396)
13. Rai KR, Sawitsky A, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219-234
14. Danese MD, Griffiths RI, Gleeson M et al (2011) An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood 117(13):3505-3513
15. Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40(8 Suppl):IV-55-IV-61
16. Klabunde CN, Legler JM, Warren JL et al (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17(8):584-590 (Pubitemid 47096709)
17. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373-383 (Pubitemid 17055592)
18. Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622-626
19. Parmelee PA, Thuras PD, Katz IR et al (1995) Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 43(2):130-137
20. de Groot V, Beckerman H, Lankhorst GJ et al (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56(3):221-229 (Pubitemid 36513483)
21. Hines RB, Chatla C, Bumpers HL et al (2009) Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 27(26):4339-4345
22. Greenland S, Rothman K (1998) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia
23. Kurth T, Walker AM, Glynn RJ et al (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163(3):262-270 (Pubitemid 43145754)
24. National Comprehensive Cancer Network (2012) NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. Version 3.2012. Retrieved from: http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. Accessed 4 Feb 2013
25. Byrd JC, Rai K, Peterson BL et al (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105(1):49-53
26. Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171-178
27. Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. doi:10.1056/NEJMoa1313984
28. Byrd JC, Murphy T, Howard RS et al (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19(8):2153-2164 (Pubitemid 32366969)
29. Huhn D, von Schilling C, Wilhelm M et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331
30. Wierda WG (2006) Current and investigational therapies for patients with CLL. Hematol Am Soc Hematol Educ Prog 2006:285-294
31. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446-5456
32. Lamanna N, Kalaycio M, Maslak P et al (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24(10):1575-1581 (Pubitemid 46638781)
33. Robak T, Smolewski P, Cebula B et al (2006) Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 107(7):1542-1550 (Pubitemid 44546915)
34. Keating MJ, O'Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088 (Pubitemid 46211313)
35. Wang M, Burau KD, Fang S et al (2008) Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 113(11):3231-3241
36. Shavers VL, Brown ML (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94(5):334-357 (Pubitemid 34257478)
37. Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care 51(5):e27-34
38. National Cancer Institute (2012) Number of Part D enrollees. National Cancer Institute, Bethesda